Medtronic reports second quarter fiscal 2024 financial results

Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; major innovative product approvals; raises fiscal year guidance dublin , nov. 21, 2023 /prnewswire/ -- medtronic plc (nyse:mdt) today announced financial results for its second quarter of fiscal year 2024 (fy24), which ended october 27, 2023. key highlights revenue of $8.0 billion increased 5.3% as reported and 5.0% organic gaap diluted earnings per share (eps) of $0.68; non-gaap diluted eps of $1.25 underlying business fundamentals are strong with broad-based, diversified growth coming from multiple businesses and geographies company increases fy24 organic revenue growth and eps guidance received u.s. fda approval for aurora ev-icd™ system and symplicity spyral™ renal denervation (rdn) system; ce mark for evolut™ fx tavr system, simplera™ standalone cgm, and pulseselect™ pulsed field ablation (pfa) system financial results medtronic reported q2 worldwide revenue of $7.984 billion, an increase of 5.3% as reported and 5.0% on an organic basis.
MDT Ratings Summary
MDT Quant Ranking